Friday, July 17, 2026

Novartis, Klinikum Bayreuth and myon.clinic launch digital RLT network

Novartis Germany, Klinikum Bayreuth GmbH and myon.clinic announced a pilot project on July 8, 2026, aimed at improving care for prostate cancer patients. The initiative, called “Vernetzter Patientenweg”, is designed to create a digital care network for radioligand therapy by connecting hospitals and specialist practices.

The project is built around the myoncare digital health platform. It is intended to bring together findings, treatment steps and documentation, while improving coordination between outpatient and inpatient care providers. Disciplines involved can include urology, nuclear medicine, oncology and radiology.

Digital coordination for complex treatment pathways

Radioligand therapy requires close alignment between diagnostics and treatment. The approach is linked to theranostics, which combines molecular imaging with targeted therapy. In practice, this creates a strong need for structured cooperation across medical specialties.

According to the partners, the platform is expected to support defined responsibilities, secure access to relevant findings and central documentation of the treatment course. A chat function is intended to facilitate communication among participating physicians. Patients are also to be integrated into the process through an app and kept informed about their treatment progress.

Bayreuth becomes first pilot site

The Department of Nuclear Medicine at Klinikum Bayreuth GmbH is the first German site involved in the project. The hospital will contribute its clinical experience to the development and testing of the digital patient pathway. Novartis describes the initiative as a pilot project with a national scope, with additional centers planned for later phases.

Alexandra Skorupa, Head of Medical Affairs Radioligand Therapy at Novartis in Germany, said the value of innovative therapies depends on patients receiving them in a timely and coordinated manner. Prof. Dr. Stefan Förster, Director of Nuclear Medicine at Klinikum Bayreuth, highlighted the role of efficient interdisciplinary collaboration in prostate cancer care.

Transferable model targeted

The partners plan to use feedback from Bayreuth and future pilot centers to refine the digital patient pathway. The goal is to create a practical model that can be used by other care networks.

Novartis lists radioligand therapy among its strategic technology platforms in oncology. The company is researching the use of these therapies across different cancer types and disease stages.